- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd stock price live, this page displays NASDAQ ADXN stock exchange data. View the ADXN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Addex Therapeutics Ltd real time stock price chart below.
What Is the Addex Therapeutics Ltd Stock Price Today?
The Addex Therapeutics Ltd stock price today is 7.5401.
What Is the Stock Symbol for Addex Therapeutics Ltd?
The stock symbol for Addex Therapeutics Ltd is "ADXN."
What Stock Exchange Does Addex Therapeutics Ltd Trade On?
Addex Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Addex Therapeutics Ltd a Good Stock to Buy?
Determining whether Addex Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADXN quote. (ISIN: US00654J2069)
What Is the Addex Therapeutics Ltd Stock Price Today?
The Addex Therapeutics Ltd stock price today is 7.5401.
What Is the Stock Symbol for Addex Therapeutics Ltd?
The stock symbol for Addex Therapeutics Ltd is "ADXN."
What Stock Exchange Does Addex Therapeutics Ltd Trade On?
Addex Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Addex Therapeutics Ltd a Good Stock to Buy?
Determining whether Addex Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADXN quote. (ISIN: US00654J2069)
NASDAQ
Currency in USD
7.5401
-1.0499(-12.22%)
Closed·
After Hours
8.0000+0.4599(+6.0994%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.5400
8.7100
52 wk Range
6.5100
13.2700
ADXN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.54008.7100
52 wk Range
6.510013.2700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADXN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Addex Therapeutics Company Profile
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Addex Therapeutics Ltd Earnings Call Summary for Q1/2025
- Q1 2025 income dropped to $100,000 from $200,000 in Q1 2024; cash reserves at CHF 2.8 million, sufficient until mid-2026
- Significant progress in drug development, particularly GABA B PAM program; stock up 1.05% in premarket trading
- Company anticipates IND-enabling studies for chronic cough program and clinical pharmacology studies for dipaglutide
- CEO optimistic about dipaglutide's potential as first-in-class drug for stroke recovery; exploring partnership opportunities
- Challenges include decreased revenue, competitive landscape in chronic cough market, and potential funding constraints for program development
Last Updated: 19-06-2025, 08:26 pm
Read Full TranscriptCompare ADXN to Peers and Sector
Metrics to compare | ADXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | 8.9x | −0.5x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price/Book | 0.7x | 2.8x | 2.6x | |
Price / LTM Sales | 24.0x | 2.4x | 3.2x | |
Upside (Analyst Target) | 249.2% | 34.7% | 44.6% | |
Fair Value Upside | Unlock | 0.9% | 6.5% | Unlock |
Earnings
Latest Release
May 15, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
1.51K / --
FAQ
What Is the Addex Therapeutics (ADXN) Stock Price Today?
The Addex Therapeutics stock price today is 7.54.
What Stock Exchange Does Addex Therapeutics Trade On?
Addex Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Addex Therapeutics?
The stock symbol for Addex Therapeutics is "ADXN."
What Is the Addex Therapeutics Market Cap?
As of today, Addex Therapeutics market cap is 7.36M.
What Is Addex Therapeutics's Earnings Per Share (TTM)?
The Addex Therapeutics EPS (TTM) is -0.06.
From a Technical Analysis Perspective, Is ADXN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Addex Therapeutics Stock Split?
Addex Therapeutics has split 1 times.
How Many Employees Does Addex Therapeutics Have?
Addex Therapeutics has 2 employees.
What is the current trading status of Addex Therapeutics (ADXN)?
As of 19 Jul 2025, Addex Therapeutics (ADXN) is trading at a price of 7.54, with a previous close of 8.59. The stock has fluctuated within a day range of 7.54 to 8.71, while its 52-week range spans from 6.51 to 13.27.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.